DoH Policies screened during the period: 1 July 2017 – 30 September 2017
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Clinical Guideline NG29 - Intravenous fluid therapy in children and young people in hospital
- NICE Clinical Guideline NG69 - Eating disorders: recognition and treatment
- NICE Clinical Guideline NG71 - Parkinson’s disease in adults (updates & replaces CG35)
- NICE Technology Appraisal TA446 - Brentuximab vedotin for treating CD30-positive Hodgkin’s lymphoma
- NICE Technology Appraisal TA448 - Etelcalcetide for treating secondary hyperparathyroidism
- NICE Technology Appraisal TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
- NICE Technology Appraisal TA450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
- NICE Technology Appraisal TA451 - Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
- NICE Technology Appraisal TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
- NICE Technology Appraisal TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE Technology Appraisal TA457 - Carfilzomib for previously treated multiple myeloma
- NICE Technology Appraisal TA458 - Trastuzumab emtansine for treating HER2 positive advanced breast cancer after trastuzumab and a taxane (review of TA371)
- NICE Technology Appraisal TA459 - Collagenase clostridium histolyticum for treating Dupuytren's contracture
- NICE Technology Appraisal TA460 - Adalimumab and dexamethasone for treating non-infectious uveitis
- NICE Technology Appraisal TA461 - Roflumilast for treating chronic obstructive pulmonary disease (review of TA244)
- NICE Technology Appraisal TA462 - Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
- NICE Technology Appraisal TA463 - Cabozantinib for previously treated advanced renal cell carcinoma
- NICE Technology Appraisal TA464 - Bisphosphonates for treating osteoporosis (part review of TA160 and TA161)
- NICE Technology Appraisal TA466 - Baricitinib for moderate to severe rheumatoid arthritis
- NICE Technology Appraisal TA467 - Holoclar for treating limbal stem cell deficiency after eye burns
- NICE Technology Appraisal TA471 - Eluxadoline for treating irritable bowel syndrome with diarrhoea